Update in: Cochrane Database Syst Rev
Instead of focusing solely on the mechanical aspects of joint problems, it recognizes the importance of overall metabolic health in patients surgical and long-term outcomes
Rosenstock J, Marquard J, Laffel LM et al (2018) Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: the EASE trials
DragicevicNSmithALinXYuanFCopesNDelicVet al
Dietitians NZ
On the other hand, recent observations show that DPP-4 inhibition, combined with the use of granulocyte colony-stimulating factor (G-CSF) under cell cycle activation conditions in cardiomyocytes, enhances myocardial regeneration and improves the function in mice after MI.63 Finally, in agreement with in vitro findings, several studies suggest that administration of the peptide GLP-1 (936) decreases myocardial injury after ischemia-reperfusion, which supports the hypothesis that treatments that inhibit the formation of this peptide may have less cardioprotective efficacy in these experimental models.25,40,48 Glucagon-like peptide-1 and cardiomyocytes in experimental models of heart failure The effects of GLP-1 (736) on cardiac viability and function have also been studied in experimental HF models (Table 2)